on 30 Apr 2019
Last Applicant/ Owned by
Bldg B, 700, Daewangpangyo-ro,; Bundang-gu,; Seongnam-si; Gyeonggi-do
KR
Serial Number
79232578 filed on 28th Feb 2018
Registration Number
5736165 registered on 30th Apr 2019
Correspondent Address
Diane J. Mason Drinker Biddle & Reath LLP
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
"TECHNOLOGY" Color is not claimed as a feature of the mark. Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of Read More
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
11th 000101
11th 000101
No 79232578
No Service/Collective Mark
No
No
No
No
No
Yes
Yes
No
No
26.03.14 -
Three or more ovals
26.03.21 -
Ovals that are completely or partially shaded
The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
| Status Date | Action Taken |
|---|---|
| 30th Apr 2024 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| 28th May 2020 | NEW REPRESENTATIVE AT IB RECEIVED |
| 13th Sep 2019 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 24th Aug 2019 | FINAL DISPOSITION NOTICE SENT TO IB |
| 24th Aug 2019 | FINAL DISPOSITION PROCESSED |
| 30th Jul 2019 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 13th May 2019 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 30th Apr 2019 | REGISTERED-PRINCIPAL REGISTER |
| 12th Feb 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 12th Feb 2019 | PUBLISHED FOR OPPOSITION |
